FDA approves antihistamine Astepro

SOMERSET, N.J. Meda Pharmaceuticals on Wednesday announced that the Food and Drug Administration has approved its prescription antihistamine Astepro (azelastine HCl) nasal spray 0.15% for the treatment of the symptoms of seasonal and perennial allergic rhinitis.

According to Meda, Astepro is the first nasal antihistamine to offer convenient once-daily dosing.

“Seasonal and perennial allergy sufferers may benefit from Astepro nasal spray 0.15%, which is 50% more concentrated than original Astepro,” stated William Berger, clinical professor, Division of Allergy and Immunology, University of California. “Based on demonstrated improvement in nasal allergy symptoms, Astepro 0.15% is a good first-line therapy option for seasonal and perennial allergic rhinitis patients suffering with nasal symptoms.”

“The approval of Astepro nasal spray 0.15% represents a significant milestone for Meda as we continue to expand and strengthen our allergy treatment franchise,” said Sharon Clarke, president and GM, Meda. “We believe Astepro nasal spray 0.15% can simplify the physician’s treatment decision for patients with seasonal and perennial allergic rhinitis, and help patients who want rapid nasal symptom relief.”

The product will be available in pharmacies in early October.